Affimed NV
NASDAQ:AFMD

Watchlist Manager
Affimed NV Logo
Affimed NV
NASDAQ:AFMD
Watchlist
Price: 0.1815 USD -34.95% Market Closed
Market Cap: $750k

Net Margin

-6 743.3%
Current
Declining
by 4 918.1%
vs 3-y average of -1 825.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6 743.3%
=
Net Income
€-70m
/
Revenue
€877k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6 743.3%
=
Net Income
$-70m
/
Revenue
€877k

Peer Comparison

Country Company Market Cap Net
Margin
DE
Affimed NV
NASDAQ:AFMD
750k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 99% of companies in Germany
Percentile
1st
Based on 3 835 companies
1st percentile
-6 743.3%
Low
-222 027.4% — -2%
Typical Range
-2% — 6%
High
6% — 85 055.6%
Distribution Statistics
Germany
Min -222 027.4%
30th Percentile -2%
Median 2.2%
70th Percentile 6%
Max 85 055.6%

Affimed NV
Glance View

Market Cap
750k USD
Industry
Biotechnology

Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

AFMD Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-6 743.3%
=
Net Income
€-70m
/
Revenue
€877k
What is Affimed NV's current Net Margin?

The current Net Margin for Affimed NV is -6 743.3%, which is below its 3-year median of -1 825.2%.

How has Net Margin changed over time?

Over the last 3 years, Affimed NV’s Net Margin has decreased from -107% to -6 743.3%. During this period, it reached a low of -7 143% on Oct 30, 2024 and a high of -107% on Aug 30, 2021.

Back to Top